through the Integration of Biosensing and AI
Ultra-Precision Sensing Technology
Model BA200
Designed for non-invasive point-of-care assessment of airway inflammation, this device combines high-sensitivity biosensor technology (0.1 ppb) with full ATS/ERS compliance. It delivers multi-parameter results—FeNO, CaNO, FnNO—in under one minute, while a patented dual-channel design ensures complete protection against cross-contamination.
More
Driven by a passion for innovation and a commitment to excellence, desire to maintain high levels of innovation, knowledge, technical expertise, service.
Committed to providing solutions for respiratory diseases, cardiovascular diseases and metabolic diseases
Become a global provider in comprehensive chronic disease solution for both professional segment and homecare.
By e-linkcare | Clinical Respiratory Insights Fractional exhaled nitric oxide (FeNO) testing is now widely recognized as a non-invasive biomarker of type 2 airway inflammation. It helps clinicians assess airway inflammation, predict corti...
A pulmonary function report tells you how well air moves in and out of the lungs. A FeNO result tells you something different: how much type 2–driven inflammation is likely present in the airways. When the two are read together, the...
Surgery is supposed to fix a problem, not create a new one in the brain. Yet for some patients—particularly those with chronic obstructive pulmonary disease (COPD)—the days and weeks after an operation can bring a quiet, frust...
Please complete the form to contact our team